MaxCyte’s delivery platform is a universal, high-performance transfection technology that significantly reduces risk and shortens biotherapeutic development timelines by enabling researchers to Perform early-stage development in the biomanufacturing host cell to ensure identification of high quality, biorelevant candidates Expand the use of transient transfection for faster candidate identification Make rapid and more informed go/no-go decisions through in-depth candidate characterization using transiently produced materials, thus reducing investments associated with stable cell line generation Expedite the transition to biomanufacturing through improved stable…